RK Smiley Research Grant Program
Since 2011 CHS has provided a member(s) with the RK Smiley Research Grant. This start-up grant is aimed at pilot projects expected to lead to larger follow-up studies funded by CIHR or other grant funding agencies. This award is named in honour of the CHS Founding President, Dr. R. Kennedy Smiley, who was also instrumental in founding the University of Ottawa’s medical school.
Award winners will receive the $30,000 CDN grant in two installments.
Deadline to apply: March 15th each year
Decision made in May.
Eligibility Criteria:
- Principal investigator must be a CHS member in good-standing
- May be clinician or scientists with a project relevant to the field of hematology
- Principal investigator on the application should be able to hold grant at their institution
Important Award information
Project length is two-years from date of approval. For example, approval was 5/15/2024 and therefore project end date is 5/15/2026.
Only one application will be received per applicant in a given year.
Preference given to groups who will benefit maximally from the start-up grant.
Be prepared! Online application requires information on project background, relevance to the field of hematology, a budget, methodology, CV upload and explanation of how the award impacts a career, what mentorship is available and/or how trainees will be engaged.
Award winners will receive the $30,000 CDN grant in two installments: first installment upon notification of winning the grant. The grant recipient must provide an update to the CHS Board at the one-year mark of the project. If the update is sufficient the second payment will be issued. The installment in the second year can include up to $3000 for publication costs.
At the end two-years the grant recipient must be prepared to submit a report that includes:
- Abstract highlighting progress/accomplishments for this project
- Limitations/challenges faced
- Budget summary (what funds were spent on; what funds remain)
- KT activities/plan
- Next steps (including future funding applications)
Grant recipients must acknowledge the funding from CHS in any publication.
RK Smiley Research Grant Winners
2023
2022
Dr. Jeannie Callum
The impact of socioeconomic status on RBC transfusion vs. IV iron infusion rates in pregnant and postpartum patients
Director of Transfusion Medicine, Pathology and Molecular Medicine, Kingston Health Sciences Centre, Kingston, ON
2022
2022
Dr. Stéphanie Forté
PULSE: a study evaluating the brain pulsatily index as a biomarker for neurovascular complications in adults with sickle cell disease
Associate Professor, University of Montreal
2021
2021
Dr. Mark McVey
Investigation of Adiponectin’s role in Regulating Transfusion-Related Acute Lung Injury
University of Toronto
2021
Dr. Syed Qadri
Deciphering the impact of acute intermittent hypoxic training on red blood cell functions: Implications in red blood cell transfusion
Ontario Tech University
2020
2020
Dr. Clinton Campbell
DEEPHEME: An Innovative Deep Learning Platform to Improve Diagnosis in Hematology
McMaster University
2020
Dr. Courtney Jones
Identification of Glutathionylated Proteins in the Mitochondria of Leukemia Stem Cells
Unity Health Network
2019
2019
Dr. Miriam Kimpton
Thromboprophylaxis with apixaban in polycythemia vera and JAK2- positive essential thrombocythemia patients: A pilot randomized controlled trial assessing feasibility.
University of Ottawa
Clinical Trials Link
2019
Dr. Kevin Kuo
A multicenter study evaluating the reliability and validity of the Rowland Universal Dementia Assessment Scale (RUDAS) and predictors of RUDAS performance in adults with Sickle Cell Disease
University of Toronto
2018
2018
Dr. Christine Cserti-Gazdewich
The Monocyte Monolayer Assay: Enhancing Care for the Untransfusables
Blood Transfusion Medicine, Toronto General Hospital
2018
Dr. Robert Kridel
Identifying new therapeutic targets for double-hit lymphoma using CRISPR-Cas screens
Medical Oncology & Hematology Princess Margaret Cancer Centre, Toronto
2017
2017
Dr. Steven Chan
Genome-Wide Identification of Synthetic Lethal Genes against TET2 Mutations in Acute Myeloid Leukemia (AML)
Princess Margaret, University Health Network, Toronto
2017
Dr. Bertrand Routy
Influence of gut microbiota on anticancer activity of immuno-therapeutic strategies in patients with multiple myeloma
McGill University, Montreal
2016
2016
Dr. Signy Chow
Next Generation Sequencing of circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) and Monitoring of Clonal Evolution in Multiple Myeloma (MM).
University Health Network, Toronto
2016
Dr. Ziad Solh
Neonatal Outcomes after Transfusion of ABO Non-Identical Blood (Neo-ABO)
McMaster University, Hamilton, Ontario
2015
2015
Dr. Yulia Lin
Setting the benchmark metric for red blood cell transfusion (RBC) to allow for assessment of optimal transfusion care: A pilot quality project at 10 hospitals.
Sunnybrook Health Sciences Centre and University Health Network, Toronto
2015
Dr. Ana Nijnik
Genome-wide Identification of p53-Regulated Genes in Hematopoietic Stem and Progenitor Cells
McMaster University, Hamilton, Ontario
2014
2014
Dr. Geerte van Sluis
A Pilot Study Investigating the Significance of Novel Factor Xa Inhibitor Interactions with Dexamethasone-Containing Regimens for Multiple Myeloma
University of British Columbia
2014
Dr. Paul Spagnuolo
Mitophagy in the development of leukemia stem cell mitochondrial phenotype
University Waterloo, School of Pharmacy
2013
2013
Dr. Brent Williams
Treatment of AML xenografted mice with CD16+NK-92 and anti-CD123 antibody – Final Report
Princess Margaret Hospital, Toronto
2013
Dr. Isaac Odame
White matter integrity and neurocognition in sickle cell patients
University of Toronto
2013
Dr. Nathalie A. Johnson
The role of FAZ mutations in chemotherapy-resistant lymphomas
McGill University, Montreal
2012
2012
Dr. Hubert Tsui
“Sensing” Hematopoiesis
University of Toronto
2012
Dr. Christian Steidl
Prognostic markers in relapsed Hodgkin lymphoma
BC Cancer Centre
2012
Dr. Michael Rauh
Myeloid-derived suppressor cells as potential novel mediators of Factor VIII tolerance in Hemophilia A
Queen’s University, Kingston, Ontario